NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Gossamer Bio, Inc. GOSS
9 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
USD 48.5M
Revenue, FY2025 · full 9-year series below
Revenue $M
Net income $M
FY2025 · Revenue 48.5 · Net income -170.4
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−351 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -352.2% · Net -351.5%
ROE
FY2024 · ROE -122.5%
The 9-year record
9 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.1 | 0.0 | 0.0 | · | · | · | · | · |
| Operating income $B | −0.2 | −0.1 | −0.2 | −0.2 | −0.2 | −0.2 | −0.2 | −0.1 | −0.0 |
| EBITDA $B | −0.2 | −0.1 | −0.2 | −0.2 | −0.2 | −0.2 | −0.2 | −0.1 | −0.0 |
| Income tax $B | −0.0 | 0.0 | 0.0 | 0.0 | · | · | 0.0 | 0.0 | 0.0 |
| Net income $B | −0.2 | −0.1 | −0.2 | −0.2 | −0.2 | −0.2 | −0.2 | −0.1 | −0.0 |
| Free cash flow $B | −0.2 | −0.0 | −0.2 | −0.2 | −0.2 | −0.2 | −0.1 | −0.1 | · |
| EPS, diluted $ | −0.75 | −0.25 | −1.18 | −2.71 | −3.13 | −3.55 | −3.29 | −22.59 | −0.74 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · |
| ROE % | · | −122.5 | −480.5 | −343.5 | −105.8 | −72.3 | −155.2 | · | · |
| Shares out B | 0.23 | 0.23 | 0.23 | 0.09 | 0.08 | 0.07 | 0.06 | 0.01 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 34 reconciliationsAUDITED
Reconciled in 9 of 19 fiscal years. 42 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2017